Theriva Biologics, Inc. (TOVX)

US — Healthcare Sector
Peers: LSTA  LIXT  IMNN  LGMK  ELDN 

Automate Your Wheel Strategy on TOVX

With Tiblio's Option Bot, you can configure your own wheel strategy including TOVX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TOVX
  • Rev/Share 0.0553
  • Book/Share 5.5696
  • PB 0.0701
  • Debt/Equity 0.0872
  • CurrentRatio 1.5312
  • ROIC -1.03

 

  • MktCap 3535817.0
  • FreeCF/Share -6.0425
  • PFCF -0.2103
  • PE -0.0438
  • Debt/Assets 0.042
  • DivYield 0
  • ROE -1.1429

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Theriva Biologics, Inc. (TOVX)

  • IPO Date 2006-12-18
  • Website https://therivabio.com
  • Industry Biotechnology
  • CEO Steven A. Shallcross CPA
  • Employees 20

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.